AstraZeneca Pharma India Ltd (ASTRAZEN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by AstraZeneca Pharma India Ltd on NSE and BSE, with an AI summary of each filing.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Others (Uncategorized) · 02 Nov 2026, 5:21 pm
Delhi High Court Grants Interim Relief to AstraZeneca Against NPPA Overcharging Demand The Hon'ble High Court of Delhi, vide order dated 29th Oct'26, directed the National Pharmaceutical Pricing Authority (NPPA) to take no coercive steps against AstraZeneca Pharma India Limited until the next hearing on 11th Jan'27. The matter pertains to an NPPA notice alleging DPCO 2013 overcharging on Symbicort Turbuhaler 160/4.5 from May'16 to Nov'25. The interim relief stays recovery proceedings for approximately Rs 151.20 crore (Rs 151,19,66,035), comprising the alleged overcharged principal and accrued interest up to 30th Oct'26.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Un-audited Financial ....
Intimation · 05 Nov 2026, 5:30 am
AstraZeneca Pharma India Schedules Board Meeting on 5th Nov'26 to Consider Q2 Results AstraZeneca Pharma India Limited announced that its Board of Directors will meet on 5th Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for designated persons remains closed from 16th Sep'26 to 7th Nov'26 (both days inclusive) in compliance with SEBI insider trading regulations.
Please find the enclosed Press Release as per the captioned subject for your reference.
Press Release · 17 Oct 2026, 12:39 am
AstraZeneca Pharma India Expands Operations with New Corporate Office in Mumbai AstraZeneca Pharma India inaugurated a 25,600 sq ft corporate office in Mumbai on 16th Oct'26 to drive its next growth phase across Oncology, Biopharmaceuticals, and Rare Diseases. The facility enhances stakeholder engagement and commercial execution as India emerges as a key contributor to its Asian operations. Over the past three years, the company introduced more than 25 new medicines and indications in India and currently runs approximately 80 global clinical trials nationwide, supported by a workforce of nearly 5,000 employees across diversified functions.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Others (Uncategorized) · 16 Oct 2026, 8:29 pm
AstraZeneca Pharma India Assigned ESG Rating of 73 by NSE Sustainability Ratings AstraZeneca Pharma India announced on 16th Oct'26 that NSE Sustainability Ratings and Analytics Limited has assigned the company an Environmental, Social, and Governance (ESG) rating of 73 for FY26. The company noted that it did not engage the rating agency, which prepared the assessment independently based on publicly available information.
Please find the enclosed intimation of the Company with respect to the captioned subject for your reference.
Others (Uncategorized) · 18 Sept 2026, 10:26 pm
ROC Imposes Penalty on AstraZeneca Pharma India Over Delayed Regulatory Filings AstraZeneca Pharma India Limited received an adjudication order from the Registrar of Companies (ROC), Bengaluru, on 17th Sep'26, imposing a penalty of Rs. 1,88,000 on the company and Rs. 50,000 each on erstwhile officers-in-default. The penalty under Section 454 of the Companies Act, 2013 pertains to a delay in filing Form MR-2 regarding the 2023 appointment of former Managing Director Dr. Sanjeev Kumar Panchal. The company attributed the delay to technical glitches on the MCA portal regarding DIN status, which was rectified in Aug'23.
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Others (Uncategorized) · 15 Sept 2026, 5:30 pm
AstraZeneca Pharma India Announces Senior Management Resignation of Dr. Sandeep Arora Dr. Sandeep Arora has resigned from his role as Director – Medical Affairs, Biopharmaceutical Business Unit and Rare Disease Business Unit at AstraZeneca Pharma India Limited, effective close of business on 15th Sep'26, to pursue external career opportunities. Dr. Arora has completed his handover duties, and the company has initiated the search for a suitable replacement to fill the senior management position.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Others (Uncategorized) · 02 Sept 2026, 11:45 pm
AstraZeneca Pharma India Receives Independent ESG Rating of 64 from Crisil for FY26 On 2nd Sep'26, AstraZeneca Pharma India disclosed receiving an ESG rating of 64 from Crisil ESG Ratings for FY26. The assessment was conducted independently based solely on publicly available information. Management clarified that the company did not formally engage Crisil for this evaluation, emphasizing the unsolicited nature of the ESG rating assignment.
Please find the enclosed document of the Company in relation to the captioned subject for your reference.
Others (Uncategorized) · 26 Aug 2026, 2:46 am
AstraZeneca India Gets Stay on NPPA Overcharging Demand Notice The Delhi High Court, on 24 Aug'26, stayed a demand notice from the NPPA concerning alleged overcharging for Betaloc-50 tablets. The NPPA alleged the company sold tablets at an MRP higher than the revised ceiling price between Jun-Jul'16. The stay is conditional on AstraZeneca depositing 15% of the demanded amount. The stay will remain in effect until the next hearing scheduled for 10 Feb'27, providing temporary relief from the full financial implication of the NPPA's recovery demand.
Please find the enclosed intimation of the Company in relation to the captioned subject for reference.
Others (Uncategorized) · 25 Aug 2026, 2:22 am
AstraZeneca Pharma India Discloses ESG Rating from Crisil On 24th Aug'26, AstraZeneca Pharma India disclosed it has been assigned an Environmental, Social, and Governance (ESG) rating of 57 by Crisil ESG Ratings & Analytics. The company clarified that it had not engaged Crisil for this rating. Crisil prepared its report independently based on publicly available information.
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Intimation · 22 Aug 2026, 3:54 am
AstraZeneca Pharma India Schedules Institutional Investor Meeting AstraZeneca Pharma India has scheduled a virtual one-on-one meeting with an institutional investor for Wed, 26 Aug'26. This interaction is disclosed under SEBI's Listing Obligation and Disclosure Requirements regulations. The company notes that the date is subject to change based on potential exigencies.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Intimation · 15 Aug 2026, 9:11 pm
AstraZeneca Pharma India Schedules Virtual Institutional Investor Meeting AstraZeneca Pharma India has scheduled a virtual one-on-one meeting with an institutional investor for Wed, 19 Aug'26. The company noted that the date is subject to potential changes due to exigencies from either party. This interaction was disclosed pursuant to SEBI's Listing Obligations and Disclosure Requirements regulations.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Annual General Meeting · 12 Aug 2026, 10:21 pm
AstraZeneca Pharma India: AGM Resolutions Passed, Rs. 36 Dividend Approved AstraZeneca Pharma India announced that all resolutions at its 47th AGM on 10th Aug'26 were passed with the requisite majority. Key approvals include the adoption of audited financial statements for the year ended 31st Mar'26 and a dividend declaration of Rs. 36 per equity share for FY25-26. The re-appointment of Ms. Bhavana Agrawal as a director and Ms. Shilpa Divekar Nirula as an Independent Director also received shareholder approval. Voting was conducted via remote e-voting and e-voting at the meeting.
Please find the enclosed Press Release of the Company for your reference.
Press Release · 11 Aug 2026, 6:13 am
AstraZeneca India Q1 FY27 Revenue Grows 30% Driven by Strong Portfolio Performance AstraZeneca Pharma India reported a 30% YoY growth in revenue from operations to INR 6,828 Mn for Q1 FY27, ended 30 Jun'26. This was driven by strong momentum in its core therapy areas: Biopharmaceuticals grew 36%, Oncology 26%, and Rare Diseases 35x. Profit Before Tax stood at INR 510 Mn. The company highlighted disciplined execution and strategic partnerships as key growth drivers, along with recent regulatory approvals for drugs like acalabrutinib and trastuzumab deruxtecan, expanding its innovative healthcare portfolio in India.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Annual General Meeting · 11 Aug 2026, 5:02 am
AstraZeneca Pharma India Declares Dividend of Rs. 36 per Share At its 47th Annual General Meeting on 10 Aug'26, AstraZeneca Pharma India (ASTRAZEN) approved key resolutions. Shareholders approved the financial statements for the year ended 31 Mar'26 and a dividend declaration of Rs. 36 per equity share. The meeting also confirmed the appointment of M/s. BSR & Co. LLP as Statutory Auditors. Additionally, the re-appointment of Ms. Bhavana Agrawal by rotation and Ms. Shilpa Divekar Nirula as an Independent Director for a second five-year term were approved.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Financial Result · 10 Aug 2026, 7:22 pm
AstraZeneca Pharma India Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Millions) ■ Revenue: 6,828 (+29.7% YoY | +18.0% QoQ) ■ EBITDA: 489 (-39.7% YoY | -19.7% QoQ) ■ EBITDA Margin (%): 7.2 (-824 bps YoY | -336 bps QoQ) ■ PAT: 379 (-32.1% YoY | -15.5% QoQ) ■ EPS (INR): 15.2 (-32.1% YoY | -15.5% QoQ)
Please find the enclosed letter of the Company as per the captioned subject for your reference.
Others (Uncategorized) · 08 Aug 2026, 5:04 pm
AstraZeneca Pharma India Gains CDSCO Nod for Breast Cancer Drug Enhertu AstraZeneca Pharma India announced on Aug 07, '26, it received permission from India's CDSCO to import and market Enhertu (Trastuzumab Deruxtecan). This approval is for an additional indication: the adjuvant treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant therapy. This paves the way for commercialization of Enhertu for this specific patient group in India, contingent on further statutory approvals.
Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve This is to inform ....
Intimation · 10 Aug 2026, 5:30 am
AstraZeneca Pharma India Board Meeting Set for Aug 10, 2026, to Approve Q1 Results AstraZeneca Pharma India (NSE: ASTRAZEN) has scheduled a Board of Directors meeting for 10 Aug'26 to consider and approve the un-audited financial results for the quarter ended 30 Jun'26. The company has also confirmed that the trading window for designated persons is closed from 16 Jun'26 to 12 Aug'26, inclusive, in compliance with insider trading regulations.
Please find the enclosed document of the Company in relation to the captioned subject for your reference.
Others (Uncategorized) · 31 Jul 2026, 2:38 am
AstraZeneca Pharma India Receives NPPA Demand Notice for Rs 148.66 Crore AstraZeneca Pharma India received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) on 29th Jul'26 for Rs. 1,48,65,83,590. This amount, inclusive of interest calculated up to 20th Aug'26, is for alleged overcharging on its Symbicort Turbuhaler inhaler between May'16 and Nov'25 under the DPCO, 2013. The company is currently evaluating the notice and considering appropriate legal action. The amount is payable within 30 days of receipt, posing a significant financial impact.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Others (Uncategorized) · 29 Jul 2026, 12:45 am
AstraZeneca Pharma India Receives NPPA Demand Notice for Rs. 79.97 Lakh AstraZeneca Pharma India received a demand notice on 27 Jul'26 from the National Pharmaceutical Pricing Authority (NPPA) for Rs. 79,97,457. This amount is inclusive of interest calculated up to 10 Aug'26. The notice alleges overcharging on the drug Betaloc-50 (Metoprolol 50 mg tablets) between Jun'16 and Jul'16 by selling above the notified ceiling price under DPCO, 2013. The company is currently reviewing the notice and must pay the demanded amount within 30 days of receipt.
Please find the enclosed letter of the Company as per the captioned subject for your reference.
Others (Uncategorized) · 28 Jul 2026, 6:51 pm
AstraZeneca India Gets CDSCO Nod for Enhertu in Breast Cancer AstraZeneca Pharma India received permission from India's CDSCO on 27 Jul'26 to import, sell, and distribute its drug Enhertu® (Trastuzumab Deruxtecan). The approval is for an additional indication: the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer. This regulatory green light allows the company to market Enhertu® for this specific cancer treatment in India, pending any other statutory approvals. The approval expands the potential market for the key oncology drug.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Dividend · 22 Jul 2026, 9:15 pm
AstraZeneca Pharma India Details FY26 Dividend Tax Withholding AstraZeneca Pharma India has announced details regarding Tax Deducted at Source (TDS) for its recommended final dividend of Rs. 36 per share for FY26. The record date is set for Jul 31, '26, with the dividend subject to shareholder approval at the AGM on Aug 10, '26. TDS rates for resident shareholders with a PAN are 10%, while those without a PAN face a 20% deduction. Non-resident TDS rates are 20% (plus surcharge) or the applicable tax treaty rate, whichever is lower.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Change in Management · 21 Jul 2026, 3:30 pm
AstraZeneca India CFO Bhavana Agrawal Resigns for Regional Group Role AstraZeneca Pharma India announced the resignation of its Executive Director and CFO, Ms. Bhavana Agrawal, effective from the close of business hours on 31st Aug'26. The departure is due to her appointment to a new regional role within the broader AstraZeneca Group. According to the filing dated 21st Jul'26, Ms. Agrawal holds no shares in the company. This management change marks a key leadership transition for the Indian subsidiary of the multinational pharmaceutical firm.
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Dividend · 19 Jul 2026, 2:05 am
AstraZeneca Pharma India Sets Record Date for FY25-26 Final Dividend AstraZeneca Pharma India Ltd. has set Jul 31, '26 as the Record Date to determine shareholder eligibility for the final dividend for the financial year 2025-26. The payment of the final dividend, if approved by the members, will be made on or before Sep 8, '26. This action follows the company's previous intimation on May 26, '26.